Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis - Top-Institutions - MDSpire

Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis

  • By

  • Yicheng Ling

  • Mengyao Wei

  • Jiapeng Luo

  • Tianxiang Gu

  • Xuan Jiang

  • May 28, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Cardiology

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology

  • #3

    University Hospital of Bonn
    University Hospital of Bonn

    Bonn, North Rhine-Westphalia

    Key Differentiators

    • Cardiology

Original Source(s)

Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis

  • by Yicheng Ling, Mengyao Wei, Jiapeng Luo, Tianxiang Gu, Xuan Jiang

  • May 28, 2026

Related Content

Erratum: Association of Gensini Score with 30-Day Mortality Rates in Acute Coronary Syndrome Patients in China

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.